Update from TGA's Pharmacovigilance Branch – June 2025

Dr Alison Stubbs Pharmacovigilance Branch Department of Health, Disability and Ageing, TGA


Session overview

- Reporting adverse events to the TGA
- PI updates from international regulators
- TGA safety communication
- Medicine shortages
- Pharmacovigilance inspection program



What we do

The Pharmacovigilance Branch of the TGA monitors the quality, safety and efficacy of medicines and vaccines after they have entered the Australian marketplace.



Pharmacovigilance at the TGA







Reporting adverse events to the TGA

Significant safety issues – SSIs

- 72-hour reporting timeframe
- Closely aligned with the European Medicines Agency's 'emerging safety issues'
- Require the TGA's urgent attention



Other safety issues

- 30-day reporting timeframe
- Safety-related changes recommended by comparable overseas regulators (that do not fit the definition of a significant safety issue)
- Safety issues from other sources that have been internally assessed and confirmed

Improving readability of case narratives

Problem

- ICSR E2B(R2) format has no set rules about spacing
- long and hard to read



Full Case Details

Case ID: AU-TGA-0000777586

Space from Spicings on Spice CAMPACHE OF SECURIORS
MANUFACTURE
CALABOTY CALABOTY SHEETS
MANUFACTURE
MANUFAC

Case markations

- Spontaneous report from Australia by a physician of a 33,000 years old female with events of refractory takeyeau artselfth Disease Activity, and non-serious Progressive Viscosias Scenools, pottern had tried and falled methotrosate, patient had tried and falled leftunomide patient had tried and falled anothloprine, patient had tried and falled adalimentals, patient had tried and failed inflicinals, and patient had tried and fulled tooligumab with Adalimumab Solution for Injection, Single Dose Pen There was no reported medical history. On unknown date(s), the patient experienced partient had tried and falled to dispurals, partiest had tried and falled inflikimab, patient had tried and falled adalimumab, perient had tried and falled acuthingstone, pattent had tided and falled beforegoide, nations had tried and folled methotroxote, refractory takayanu arteritis Disease Activity, Progressive Vascular Stenosis. Leffunomide, Michistresate, todifizumab, infliatmob, agathlogeles were also considered suspect. The patient had tried and falled methotrenate, leflunomide, azathioprine, adelimumab, infliximab and tocilisumab as steroid sparing agents. Her Current Treatment was prednisolone 25mg daily. Her tooliusmab was ceased due to orgoing acritic inflammation on Magnetic resonance angiography and ongoing symptoms as of 50 Jun 2023 as there was emerging evidence showing potential efficacy of SAE inhibitors in Takayassi arteritis. She was a young woman with small children and was at high

failed tocilizumab and refractory takayasu arteritis Disease Activity with Adalian umah Solution for Injection was Not Provided Abbide's opinion was that the causality for the event(s) of Progressive Vascular Stenosis, patient had tried and failed adalmumab, patient had tried and falled azathioprine, potient had tried and failed infliximab, patient had tried and failed leffunomide, patient had tried and failed methotresate, patient had tried and failed tecilizumab and refractory takayasu arteritis Disease Activity with Leffunomide (Leffunomide) was Not Provided AbbVIa's opinion was that the causality for the event(s) of Propressive Vaccular Stanock, patient had tried and failed adalimumab, patient had tried and falled apathlooring, patient had tried and falled inflinimals, patient had tried and falled left unomide, patient had tried and falled methotrexate, patient had tried and failed to dilaumab and refractory takayasu arteritis Disease Activity with Toolli ournals (Toollinumals) was Not Provided AbbVie's opinion was that the causality for the event(s) of Propressive Vascular Stenock, nationt had tried and failed adalimumab, patient had tried and failed arathioprine, patient had tried and falled inflivimab, patient had tried and falled left unomide, patient had tried and failed methotrevate, patient had tried and failed tocilinumab and refractions takes as a stresitis Dinease Activity with Methodresate (Methodresate sodium) was Not Provided AbbVie's opinion was that the causality for the event(s) of Progressive Vascular Stenosis, patient had tried and failed adalimumab, patient had tried and failed azathioprine, patient had tried and failed infliximab, potient had tried and failed leffunomide, patient had tried and failed methotrexate, patient had tried and failed totilizumab and refractory takayasu arteritis Disease Activity with Inflaimab (Inflaimab) was Not Provided Abbitle's opinion was that the causality for the event(s) of Progressive Vascular Stenock, patient had tried and failed adalignment, patient had tried and failed azathloprine, patient had tried and falled infibimab, patient had tried and falled leflunomide, patient had tried and failed methotrexate, patient had tried and falled tocilizumab and refractory takayasu arterids Disease Activity with Acathloprine (Azathloprine) was Not Provided AbbVie's opinion was that the causality for the event(s) of Progressive Vascular Stenosis, patient had tried and falled adalimumab, patient had tried and falled auathioprine, patient had tried and falled infliximab, patient had tried and falled leftunomide, patient had tried and failed methotresate, nationt had tried and failed to disamab and refractory takayanu arteritis Disease Activity with Adalimumab Solution for Injection was

insk of significant risk of morbidity and even mortality from excessive steroid exposure and ongoing disease activity. Totacitivib had an acceptable side effect profile in this age group to which she was at low risk of cardias events/malignancy due to her young age. Cassalities ---reporter's caseality for the event(s) of Progressive Vascular Stenosis, patient had tried and falled adalimumals, patient had tried and falled apathioprine, patient had tried and failed inflatmab, patient had tried and failed leftunomics, patient had tried and failed methotreuste, pitters had tried and failed todifinanch and refractory takayana arteritis Disease Activity with Laflumomide (Leflumomide) was Not Provided The reporter's causality for the event(s) of Progressive Vascular Stenovis, patient had tried and failed adalimentab, patient had tried and failed apathioprine, patient had tried and failed infliximab, patient had tried and failed influenceate, nations had tried and failed methodrosate, nations had tried and failed tocilipumab and refractory takeyeau arteritis Disease Activity with Tocilizumab (Tocilizumab) was Not Provided The reporter's causality for the event(s) of Progressive Vascular Stenosis, patient had tried and falled adollesumab, patient had tried and falled arathloprine, patient had tried and failed infligious, patient had tried and failed leftenemide, patient had tried and failed methotrexate, patient had tried and failed toolligamab and refractory takayasu arteritis Disease Activity with Muthotnesate (Muthotnesate sedium) was Not Provided The reporter's causality for the event(s) of Progressive Vascular Stenovis, patient had tried and failed adalimsmab, patient had tried and failed anathioprios, patient had tried and failed influenals, patient had tried and falled leffurcenide, patient had tried and falled methotresate, patient had tried and failed todilisumab and refractory takayosu arteritis Disease Activity. with Inflinimab (Inflatmab) was Not Provided The reporter's causality for the event(s) of Progressive Vascular Stenosis, patient had tried and failed adalmsmals, patient had tried and failed apathioprine, patient had tried and failed inflormab, patient had tried and failed leffunomide, patient had tried and falled methotrepate, patient had tried and falled notifition ab and refractors takayasu arteritis Disease Activity with Assthioprine (Assthioprine) was Not Provided The reporter's causality for the event(s) of Progressive Vascular Stonosis, patient had tried and failed adalimumats, patient had tried and failed anathroprine, patient had tried and falled inflationals, patient had tried and falled leflunomics, patient had tried and failed methotrosots, patient had tried and

Not Provided Reporter's Alternative Etiology for refractory takayasu arteritis Disease Activity with Leffunomide (Leffunomide): Reporter's Alternative Etiology for refractory takayasu arteritis Disease Activity with Tocilizumab (Tocilizumab): Reporter's Alternative Etiology for refractory takayasu arteritis Disease Activity with Methotrexate (Methotrexate sodium): Reporter's Alternative Eticlogy for refractory takayosu arteritis Disease Activity with Adalimumab Solution for Injection: Reporter's Alternative Etiology for refractory takayasu arteritis Disease Activity with Infliximab (Infliximab): Reporter's Alternative Etiology for refractory takayasu arteritis Disease Activity with Agathioprine (Agathioprine); Reporter's Alternative Etiology for Progressive Vascular Stenosis with Adalimumab Solution for Injection: Reporter's Alternative Etiology for Progressive Vascular Stenosis with Leflunomide (Leflunomide): Reporter's Alternative Etiology for Progressive Vascular Stenovis with Tocillirumab (Todilizumabl): Reporter's Alternative Etiology for Progressive Vascular Stenosis with Methotrexate (Methotrexate sodium): Reporter's Alternative Etiology for Progressive Viscoilar Stenosis with Infliximab (Infliximab): Reporter's Alternative Etiology for Progressive Vascular Stenosis with Azathioprine (Azathioprine): Reporter's Alternative Eticlogy for patient had tried and failed toollingmah with Adalimumab Solution for Injection: Reporter's Alternative Etiology for patient had tried and failed leffunomide with Adalimumab Solution for Injection Reporter's Alternative Etiology for patient had tried and failed azathioprine with Adalimumab Solution for Injection: Reporter's Alternative Utiology for patient had tried and failed infliximab with Methotrexate (Methotrexate sodium): Reporter's Alternative Etiology for patient had tried and failed infliximals with Azathioprine (Azathioprine): Reporter's Alternative Etiology for patient had tried and failed left-nomine with Socilinamab (Socilinamable Reporter's Alternative Etiology for patient had tried and falled infliximals with Adelimuma's Solution for Injection: Reporter's Alternative Etiology for patient had tried and failed methotrerate with Adalimumab Solution for Injection: Reporter's Alternative Eticlogy for patient had tried and falled adalimumab with Adalimumab Solution for Injection: Reporter's Alternative Diology for patient had tried and failed tocilizumab with infliximab [infliximab]: Reporter's Alternative Etiology for patient had tried and failed infliximab with Leflunomide (Leflunomide): Recorder's Alternative Dickogy for national had tried and failed tooliks much with Tocilizumsb (Tocilizumsb): Reporter's Alternative Etiology for patient had tried

and failed anathionrine with inflatmah (inflatmah): Senorter's Abernative Etfology for patient had tried and falled tocillaumab with Methotresate (Methotrexate sodium): Reporter's Alternative Etiology for patient had tried and failed methotrexate with Leflunomide (Leflunomide): Reporter's Alternative Etiology for patient had tried and failed adalimumab with Tocilizumab (Todiizumab): Reporter's Alternative Eticlogy for patient had tried and failed azathioprine with Azathioprine (Azathioprine): Reporter's Alternative Etiology for patient had tried and failed methotrenate with infliximab (Infliximab): Reporter's Alternative Etiology for patient had tried and failed methotrexate with Methotrerate (Methotrerate socium): Reporter's Alternative Etiology for patient had tried and failed leflunomide with Methotrexate (Methotrexate sedium): Reporter's Alternative Diology for patient had tried and failed left incomide with inflixionals (beflixionals): Executar's Alternative Etiology for partient had tried and falled anythioprine with Methorrevate (Methorrevate sodium): Reporter's Alternative Etiology for patient had tried and failed adalimumab with Azethioprine (Azethioprine): Reporter's Alternative Etiology for patient had tried and falled methotroxate with Azathioprine (Azathioprine); Reporter's Alternative Eticlogy for patient had tried and falled infliximals with Todilizumab (Todilizumab): Reporter's Alternative Etiology for patient had tried and failed leffunomide with Leffunomide (Leffunomide); Reporter's Alternative Etfology for patient had tried and failed methotresate with Tocilizumab Cloditzumabl: Reporter's Alternative Eticlopy for patient had tried and failed leffunomide with Azathioprine (Azathioprine): Reporter's Alternative Etiology for patient had tried and failed tocilizumab with Leffunomide (Leffunomide); Reporter's Alternative Etiology for patient had tried and failed tocilizamab with Azathioprine (Azathioprine): Reporter's Alternative Etiology for patient had tried and failed adalimumab with Infliximab (Infliximab): Reporter's Alternative Etiology for patient had tried and failed arathioprine with Tocilizumab (Todilpumable Reporter's Alternative Eticlogy for patient had tried and falled infliximab with infliximab (Infliximab): Reporter's Albernative Etiology for patient had tried and failed azathloprine with Leflunomide (Leflunomide): Reporter's Alternative Etiology for patient had tried and failed adalimumab with Leffunomide (Leffunomide): Reporter's Alternative Etiology for patient had tried and falled adalmumab with Methotrevate i Methotrevate sodiumic AbbWe's Alternative Etiology for refractory takauasu arteritis Disease Activity with

Methocrewite (Methocrewite sodium): AbbVIe's Alternative Etiology for patient. had tried and failed methotrevate with Leffunomide (Leffunomide): AbbVio's Alternative Etiology for patient had tried and falled adalmumab with flocifizumab (flocifizumab): AbbVie's Alternative Etiology for patient had tried and falled azathloprine with Azathloprine (Azathloprine): AbbVie's Alternative Etiology for patient had tried and failed methotresate with infliximab (infliximab): AbbVie's Alternative Eticlogy for patient had tried and failed methodrevate with Methodrevate (Methodrevate sodium): Abb/Vie's Alternative Etiology for patient had tried and falled leffunomide with Methotresate (Methotrevate sodium): AbbVie's Alternative Etiology for patient had tried and failed leftunceside with inflormab [inflormab]; AbbWe's Alternative Etiology for pattent had tried and falled anathioprine with Methotrevate (Methotrevate sodium); AbbVie's Alternative Etiology for patient had tried and failed adalimumab with Azathioprine (Azathioprine): AbbVie's Alternative Etiology for patient had tried and failed methotrevate with Anathloprine (Anathloprine): AbbVie's Alternative Etiology for patient had tried and failed infliximab with Toolf numb (Toolf numb): Abbitie's Alternative Etiology for patient had tried and failed leffunomide with Leffunomide (Leffunomide): AlbVie's Alternative Etiology for patient had tried and failed methotrecate with Totil number (Socilizamab): AbbWe's Alternative Otlology for patient had tried and failed leftunomicle with Azethioprine (Azethioprine): AbbMe's Alternative Eticlogy for patient had tried and falled to illinumals with Leffuncavide (Leffuncavide): AbbMa's Alternative Effology for patient had tried and failed codificamab with Azethkoprine (Azethkoprine): AbbVW's Alternative Etiology for patient had toled and failed adalimumub with Inflinimab (Inflinimab): AbbVie's Alternative Etiology for patient had tried and failed azathioprine with Toolf zumab (Yorlfzumab): AbbVIe's Alternative Edology for patient had tried and failed inflormab with Inflikimab (Infliximab): AbbVio's Alternative (Itiology for patient had tried and falled azathioprine with Leffunomide (Leffunomide); AbbVie's Alternative Etfology for patient had titled and falled adaltmumals with Leffenomide (Leffunomide): AbbVile's Alternative Etiology for patient had tried and failed adalmumab with Methotrevate (Methotrevate socium): Change History --- Ciri 30 Jun 2023, received undates to current event information. Medical History - Not reported. Primary reporter contact for

lot number information was not available.

Leffunceride (Leffunceride): Abbide's Alternative Eticlopy for refractory takeyas a arteritis Elsease Activity with Tocilizumab (Tocilizumab): AbbMe's Alternative Etiology for refractory takayasu arteritis Disease Activity with Methotresate (Methotrecate sodium): AbbVie's Alternative Etiology for refractory takayasu arteritis Disease Activity with Adalimumab Solution for Injection: AbbVie's Alternative Etiology for refractory takayasu arteritis Disease Activity with Infliximab (Infliximable AbbVie's Alternative Etiology for refractory takayasu arteritis Disease Activity with Azathioprine [Azathioprine]: AbbiVie's Alternative Etfology for Progressive Vascular Stenosis with Adalimumab Solution for Injection: AbbWe's Alternative Ctiology for Progressive Vascular Stenosis with Leflunomide (Leflunomide): AbbVie's Alternative Etiology for Progressive Vaccular Stenosis with Tocillaumab (Tocillaumab): AMVIe's Alternative Etiology for Programming Vasco for Stangaria with Matheterista (Matheterista and cod) AbbVie's Alternative Etiology for Progressive Vascular Stenesis with Inflinimab (Inflisionabl: AbbWe's Alternative Eticlosy for Progressive Vascular Stancels with Azathioprine (Azathioprine): AbbVie's Alternative Etiology for patient had tried and failed tecilizumab with Adalimumab Solution for Injection: AbbVie's Alternative Etiology for patient had tried and failed leflunomide with Adallmumab Solution for Injection: AbbMe's Alternative Eticlogy for patient had tried and falled authoraine with Adalimanus Solution for Infection: AbbVio's Alternative Etiology for patient had tried and failed inflivimab with Methotrevate (Methotrevate sodium): AbbVis's Alternative Etiology for patient had tried and failed infliximals with Azathioprine (Azathioprine): AbbVie's Alternative Etiology for patient had tried and failed leffunomide with Todil zumab (Todil zumab): AbbYie's Alternative Diology for patient had tried and failed inflormab with Adelimumab Solution for Injection: AbbVie's Alternative Etiology for patient had tried and failed methotrexate with Adalimumab Solution for Injection: AbbVie's Alternative Etiology for patient had tried and failed adalimumab with Adalimumab Solution for Injection: AbbVie's Alternative Etiology for patient had tried and failed tocilioumab with Infliximab (Infliximab): AbbVie's Alternative Etfology for patient had tried and failed infliximab with Leffunemide (Loffunomide): AbbWle's Alternative Etiology for patient had tried and falled tocilizumab with Tocilizumab (Tocilizumab); Abbirle's Alternative Etiology for patient had tried and falled authloprine with inflatmab (inflatmab): Abb/Ge's Alternative Etiology for patient had tried and failed tocilizumab with

	God Bern	Management of Steel	CHICAGO
Drag institution			Veldore
Drug inshelling			Unknown
ing indicate			Secure.
Drug marketine			Vennove
ingrafeme			URCOME
ongradume.			Limitable.
Stema Setella			net receive set to
desired and the same			recruet, regard
recolar percel-			Date score

Stragg office pitters	Strate of Administration, Subsolvence	
Support datelor		
receptor:	"Mayasi's arrantis	
AUTHOR Town	Uterture	

Inarge information.	Reside of Administration, reformation that Provided to Source
Destroys posis	
relution:	Program for autopies indication
Action Name	9797947

is account to laptore	N HAME	
Tribage Print Workship	South of Administrators Interrupted Aut Provided by Sporter	
TAKETHER SHIPE		
relitation:	thing you for exercises individue	
Action Telepo	Sideman.	

Drange information	Seeks of name about a time to the matter than the country to be a seeker-	
Treatment dates.		
Mission.	Drug use for wenture indication	
Arrest Talans	cremen	

Suprement details:	
relication	Drug up for encours indication
Action Toron	SAMPLE STATE OF THE SAMPLE

al recognises to to	J1963-194911
Strage information.	And Paletrophy obvious recording species
twictions plotted.	
nitatio	ting on to encome intration
Arrive Tales	999M

Improving readability of case narratives

Solution

- spacing
- subheadings

Required evidence base

Boxed warnings should generally be based on observed data from clinical and sometimes non-clinical sources.

Clinical data may be from:

- · market authorisation studies
- post-market sources including post-market studies (either sponsor initiated or investigator initiated) and literature or pharmacovigilance activities
- · additional analyses of data
- off-label use of the medicine (in exceptional circumstances).


Generally, a boxed warning will be required on the basis of direct evidence from the particular medicine. Sometimes a boxed warning may also be required:

- on the basis of indirect evidence or an anticipated effect
- if a particular safety signal occurs for one medicine within a class, but not others.



Updates by comparable overseas regulators

When an overseas regulator adds safety information to their PI/CMI, the TGA expects you to update the Australian PI and CMI accordingly.





TGA safety communication

- Product Information updates are listed monthly on the TGA website
- Medicine Safety Update articles are published on the TGA website when the information is clinically important or of special interest
- Summaries and links to Medicine Safety
 Update articles appear in Australian Prescriber
 and are disseminated via the Primary Health
 Network


TGA Medicine Safety Updates



- More prominent warnings about serious side effects for fluoroquinolone antibiotics
- Azithromycin and rare risk of cardiovascular death
- Promethazine hydrochloride (Phenergan) not to be used in children under 6
- New safety warnings for isotretinoin (Roaccutane)
- Avoiding paediatric dosing errors with risperidone
- Updated warnings for Respiratory Syncytial Virus vaccines Arexvy and Abrysvo



Understanding the impact of shortages and discontinuations



Public consultation in 2024

217 respondents

Organisations


- 32 health professional
- 26 medicine industry
- 6 consumer
- 7 government

Individuals

- 116 consumers
- 19 prescribers
- 9 pharmacists
- 2 other health professionals

Understanding the impact of shortages and discontinuations

Market research in 2024



800 survey respondents + 17 one-to-one interviews

- 207 prescribers
- 197 pharmacists
- 295 impacted consumers
- 101 non-impacted consumers

Challenge themes

That people experienced relating to medicine shortages and discontinuations

1 Inconsistent, inaccurate or not timely information about medicine availability

Lack of reporting requirements for shortages of specific medicines of public interest that are not currently captured by mandatory reporting framework

3 Low confidence in medicine supply leading to stockpiling and reduced demand predictability





Challenge themes

Limited therapeutic alternatives for niche treatments

Time-consuming manual administrative and regulatory processes, leading to delays and barriers to patients accessing alternatives

Perceived inequitable distribution of and access to limited stock (*outside of TGA remit*)

TGA Medicine Shortages and Discontinuations improvements roadmap

Priority Outcome 1

Updated legislative framework to better meet public information needs

Priority Outcome 2

Critical improvements to data and digital infrastructure

Priority Outcome 3

Better access to shortages information for health professionals

Priority Outcome 4

Better sponsor predictions on medicine demand and shortages



1

2

3

4

Priorities announced

November 2024



Priority Outcome 1

Updated legislative framework

1.1 Reportable medicines: Include more critical non-prescription medicines in the mandatory reporting framework. – Completed March 2025

1.2 TGA access to medicine supply data: Include

a provision in the *Therapeutic Goods Act 1989* to require sponsors of any approved medicine to provide the TGA with detailed supply information on request.

1.3 Earlier notice of discontinuations:

Require sponsors to provide 12 months' notice to the TGA of a decision to permanently discontinue a reportable medicine in Australia.



Therapeutic Goods (Reportable Medicines) Determination 2025

I, Nicholas Henderson, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 5 March 2025

5 Reportable medicines

The medicines set out in Schedule 1, being medicines that are registered goods, are determined to be reportable medicines for the purposes of subparagraph 30EH(1)(b)(ii) of the Act.

- Public consultation closed on 13 January 2025
- 25 additional non-prescription medicines were added to the reportable medicines legislative instrument
- New medicines include sodium chloride 0.9% IV fluids, permethrin for scabies and hydroxocobalamin injections
- This new legislative instrument is now in effect

Feedback on proposals to update the *Therapeutic Goods Act* 1989

TGA access to supply data of any approved medicine on request

- Shortages of non-reportable medicines can have significant impacts on Australians
- Balanced approach to improving TGA monitoring without significant increase in regulatory burden to sponsors

"...allows for proactive steps to be taken where local and international signposts on shortages are brought to the attention of TGA in the absence of formal notice from sponsors"

- Government respondent

"Products excluded from regulatory access frustrate national efforts to implement effective mitigation strategies when critical shortages occur"

- Health professional organisation

Feedback on proposals to update the *Therapeutic Goods Act 1989*

Earlier notice of discontinuations – uniform 12-month notice period

- Most support from government, health professional and consumer organisations
- Clearer reporting requirements
- Importance of maintaining the existing clause 'or as soon as practicable after the decision is made'
- Need for flexibility in timing of TGA publication of discontinuations – risks of stockpiling and wastage
- Variation from discontinuation reporting requirements in other countries



Priority Outcome 3

Better access to shortages information for health professionals

National coordination and communication framework for communicating about medicine shortages and discontinuations and coordinating mitigating actions



Health professionals to be more aware of medicine shortages and discontinuations and coordinated management actions



Reduce the duplication of communication efforts for hospitals and health organisations



Patients to face reduced impacts from shortages and discontinuations

For more information

Visit our website to see what we're doing to improve the monitoring of medicine shortages and discontinuations and reduce their impact:

www.tga.gov.au






Update on TGA's Pharmacovigilance Inspection Program

Findings & changes

Amanda Chan Senior Pharmacovigilance Inspector Department of Health, Disability and Ageing, TGA


Pharmacovigilance inspections in 2022

- 9 pharmacovigilance inspections conducted
- Average 6.9 deficiencies per inspection




Pharmacovigilance inspections in 2023


- 8 pharmacovigilance inspections conducted
- Average 7.3 deficiencies per inspection



Pharmacovigilance inspections in 2024

- 6 pharmacovigilance inspections conducted
- Average 6.7 deficiencies per inspection







Average deficiencies per inspection by grade




Number and grading of deficiencies in 2022



Number and grading of deficiencies in 2023



Number and grading of deficiencies in 2024



Improvement in deficiency findings over the years

- Case management
- Quality management system



Total number of deficiencies in case management over time



Total number of deficiencies in QMS over time



Limited changes in deficiency findings over the years

- Reference Safety Information
- Management of SSIs
- Post-approval commitment
- A-PVCP and QPPVA



Evolution of PVIP & next steps

Ongoing improvement

- Regular review to fine-tune processes
- Embracing new technologies and methodologies to improve inspection process
- Align with global trends

Work collaboratively with stakeholders

 Encourage feedback to identify areas for enhancement



Common feedback

Inspections are:

- too long
- rigorous
- too detailed
- too onerous
- not fit for purpose



But also ...

Inspections have:

- been an excellent educational tool
- identified gaps in processes
- allowed for an open dialogue with the TGA
- identified the need for extra resourcing
- flagged common misconceptions across the sector and provided clarity
- allowed the ability to work with the TGA to ensure there is clear understanding of the requirements





Our aims

- Limit and revise inspection timeframes
- Formulate more focused document requests
- Review the scope of the inspection
- Use technological advances to gather information and documents



We are also aiming to:

- increase the number of inspections per year
- re-inspect where appropriate
- empower sponsors with the responsibility of CAPAs with limited regulatory involvement
- identify areas of specific need and provide targeted education
- publish more concise biannual PVIP reports

Therapeutic Goods Administration (TGA)

Exhibition booth No.60

Want to chat with me further? Come visit us.



